摘要
随着肿瘤分子生物学的发展,肿瘤细胞增殖和转移过程中信号通路作用机制研究的不断深入,使肿瘤治疗进入全新的时代.表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)过表达和/或突变与许多肿瘤相关,其中典型的就是晚期胃癌及胃食管交界癌.ToGA研究是胃癌治疗的一个里程碑,他确立了曲妥珠单抗在胃癌HER2阳性患者的治疗地位.本文总结HER2的生物学特性及在胃癌组织和血清中的表达和意义;归纳曲妥珠单抗在HER2阳性胃癌的应用前景及晚期胃癌靶向治疗的中国专家共识;概述关于HER2阳性胃癌最新的基础和临床研究状况.总之,HER2与胃癌的预后无关,各靶向治疗的有效联合很可能成为今后治疗的方向.
With the development of tumor molecular biology, the mechanisms responsible for metastasis and the proliferation and growth of tumor cells have become unmasking, which makes cancer treatment enter into a new era. HER2 is overexpressed or mutated in many kinds of tumors and have been associated with many malignant tumors, typically including advanced gastric and gastroesophageal junction cancer. The ToGA study is a milestone in the treatment of gastric cancer, which established the position of trastuzumab in the treatment of HER2-positive gastric cancer. In this review, we discuss the biological characteristics of HER2 and its role in the treatment of gastric cancer, the application prospects of trastuzumab in the treatment of gastric cancer, and the Chinese experts’ consensus statement on targeted therapies for advanced gastric cancer. We also summarize the latest advances in basic and clinical research of HER2 positive gastric cancer. All in all, HER2 has nothing to do with the prognosis of gastric cancer. The combination of target-therapies may become a promising weapon for treatment of gastric cancer.
出处
《世界华人消化杂志》
CAS
北大核心
2014年第1期31-38,共8页
World Chinese Journal of Digestology
关键词
胃癌
人类表皮生长因子受2
曲妥珠单抗
靶向治疗
发病机制
Gastric carcinoma
Human epidermal growth factor receptor 2
Trastuzumab
Targeted therapy
Pathogenesis
